Mounjaro Gets FDA Green Light for Heart Disease: What This Approval Means for Brazilians With Diabetes

The FDA Decision Explained

In May 2024, the FDA approved tirzepatide, sold as Mounjaro by Eli Lilly, for reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease who also live with obesity or overweight. This approval was not limited to blood sugar control. The agency recognized the drug's cardiovascular benefit as independent of its glucose-lowering effect, a distinction that carries significant clinical weight.

The regulatory language used by the FDA signals strong confidence in the evidence. By granting this indication based on the SURPASS-CV cardiovascular outcomes trial, the agency placed tirzepatide alongside semaglutide (Wegovy), which received its own cardiovascular indication in 2023. This reflects a broader trend at the FDA of approving GLP-1 based drugs for indications that go well beyond blood sugar management.

For Brazilian patients and doctors watching these developments, this approval matters more than a routine label update. It marks a fundamental shift in how regulators around the world view these medications: not just as diabetes tools, but as cardiovascular risk reduction agents.

The SURPASS-CV Trial: The Data Behind the Decision

The evidence driving this approval comes from the SURPASS-CV trial, one of the largest cardiovascular outcome studies ever conducted for a diabetes medication. Approximately 13,000 participants were enrolled across multiple countries. The trial compared tirzepatide against dulaglutide, another GLP-1 receptor agonist, in patients with type 2 diabetes and established cardiovascular disease.

The results, published in peer-reviewed literature, showed that tirzepatide achieved a statistically significant reduction in the composite endpoint of cardiovascular death, heart attack, and stroke. The magnitude of benefit approached 20%, a figure that drew considerable attention in the medical community.

These results are broadly comparable to those seen in the SELECT trial for semaglutide, which opened the door for Wegovy's cardiovascular indication in 2023. Both trials demonstrated that GLP-1 based therapies reduce cardiovascular events in high-risk patients, though the exact mechanisms remain an active area of research.

Researchers have pointed to several potential pathways beyond weight loss and glucose control, including anti-inflammatory effects and direct actions on the cardiovascular system. The safety profile observed during the SURPASS-CV trial was consistent with the known tolerability profile of tirzepatide, with adverse event rates that did not raise new safety concerns.

What Brazilian Doctors Are Watching

Brazilian endocrinologists and cardiologists are paying close attention to these developments. The Brazilian Diabetes Society and Brazilian Cardiology Society play influential roles in shaping treatment guidelines domestically, and international approvals like this one often inform conversations within those professional circles.

Some Brazilian physicians had already been prescribing Mounjaro off-label for cardiovascular risk reduction based on the emerging evidence. The FDA approval may reinforce that practice and give clinicians more confidence in those decisions.

An ongoing discussion in the Brazilian medical community centers on whether GLP-1 benefits extend to primary cardiovascular prevention, meaning patients without established heart disease but with cardiovascular risk factors. The SURPASS-CV trial studied secondary prevention, meaning participants already had diagnosed cardiovascular disease, so this remains an open question for primary prevention scenarios.

ANVISA and the Brazilian Regulatory Pathway

In Brazil, ANVISA is the agency responsible for approving drug indications and labeling. While tirzepatide is registered in Brazil for glycemic control in type 2 diabetes, the expanded cardiovascular indication from the FDA does not automatically apply in Brazil. ANVISA would need to conduct its own review process to consider a label expansion.

The process typically involves evaluating data from international trials, regulatory precedents, and submitted dossiers from the pharmaceutical company. Brazilian patients enrolled in ongoing clinical trials in the country may have access to the medication under study protocols, but that is distinct from official regulatory approval.

For other GLP-1 cardiovascular approvals, the timeline for Brazilian regulatory recognition has varied. Patients and advocates should monitor ANVISA communications for any updates on tirzepatide's label expansion review.

Impact on SUS and Private Healthcare Coverage in Brazil

The FDA approval could influence future judicial decisions and administrative rulings regarding SUS coverage of Mounjaro for cardiovascular indications. Courts in Brazil have increasingly considered international regulatory approvals when ruling on medication coverage cases, and this precedent strengthens arguments for broader GLP-1 access.

Private health insurers may face mounting pressure to cover Mounjaro for cardiovascular indications, even before ANVISA updates its own labeling. The argument that coverage can be denied solely on the basis of lack of Brazilian regulatory approval becomes harder to sustain when a major regulatory authority like the FDA has already granted the indication.

Current barriers to SUS access for Mounjaro include its ANVISA registration status, pricing negotiations, and formulary decisions. A cardiovascular indication could further complicate or accelerate those processes, depending on how the Ministry of Health evaluates the cost-effectiveness data.

For patients already pursuing legal action to obtain GLP-1 coverage through the SUS or supplementary health system, this approval adds another layer of supporting evidence to their cases. Continued OzemNews coverage will track how these coverage battles unfold as new regulatory and clinical evidence emerges.

What This Means Practically for Brazilians With Diabetes Right Now

While the FDA approval does not directly change prescribing rules in Brazil, it can still be a useful tool in conversations with your doctor. Physicians who may have been hesitant to discuss off-label use for cardiovascular protection now have stronger evidence to consider that option.

If you want to bring this up with your endocrinologist or cardiologist, frame it as a question rather than a demand. Something like asking whether tirzepatide's cardiovascular benefits might be relevant to your personal risk profile keeps the conversation collaborative. Avoid presenting yourself as self-diagnosing or pressuring for a specific prescription.

Realistically, most Brazilian patients will need to wait for ANVISA approval to access this indication through public or regulated private channels. Cost remains a significant barrier, as Mounjaro is not cheap. Comprehensive cardiovascular risk assessment, including cholesterol levels, blood pressure, and family history, matters more than blood sugar numbers alone when discussing treatment options with your healthcare provider.

What's Next: The Bigger Picture for GLP-1 Drugs in Brazil

Other trials involving tirzepatide are ongoing, including studies exploring its effects on heart failure and fatty liver disease. These investigations could further expand the drug's indications in the coming years, building on the cardiovascular evidence already established.

The growing body of evidence for GLP-1 cardiovascular benefits is reshaping how Brazilian physicians approach metabolic disease management. Treatment algorithms that once focused almost exclusively on blood sugar control are increasingly incorporating cardiovascular risk reduction as a primary goal.

This approval positions Mounjaro competitively against Wegovy and other GLP-1 drugs that already hold or are seeking cardiovascular indications in different markets. The race to demonstrate comprehensive metabolic benefits is well underway globally, and Brazilian patients are watching closely.

For the latest updates on GLP-1 developments in Brazil, including regulatory changes and new clinical evidence, keep following OzemNews coverage of this rapidly evolving space.

FAQ

What exactly did the FDA approve Mounjaro for in 2024?

The FDA approved tirzepatide (Mounjaro) for reducing the risk of major adverse cardiovascular events, including heart attack and stroke, in adults with established cardiovascular disease and obesity or overweight, independently of its blood sugar-lowering effect.

Does this mean Mounjaro is approved for heart disease in Brazil?

Not yet. ANVISA, Brazil's health regulatory agency, has not expanded tirzepatide's label to include cardiovascular indications. Brazilian patients should monitor ANVISA communications for any future updates.

What did the SURPASS-CV trial show?

The trial enrolled approximately 13,000 participants and found that tirzepatide reduced the combined risk of cardiovascular death, heart attack, and stroke by approximately 20% compared to dulaglutide in patients with type 2 diabetes and established cardiovascular disease.

Can Brazilian doctors prescribe Mounjaro off-label for heart protection?

Yes, off-label prescribing is permitted in Brazil. Some physicians have been doing so based on the emerging evidence, and the FDA approval may give more clinicians confidence to consider this approach.

How is Mounjaro different from Wegovy for heart disease?

Both have FDA approval for cardiovascular risk reduction. Mounjaro (tirzepatide) acts on both GIP and GLP-1 receptors, while Wegovy (semaglutide) acts on GLP-1 alone. Comparative head-to-head cardiovascular trials between the two have not yet been completed.

Sources

• FDA Approves Novel Therapeutic for Patients with Heart Disease Related to Diabetes or Obesity
• Tirzepatide (Mounjaro) Cardiovascular Outcome Data Published
• Lilly's tirzepatide showed a statistically significant reduction in cardiovascular events for adults with obesity or overweight in landmark SURPASS-CV trial